Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

Experimental biology and medicine (Maywood, N.J.)·2026

Same author

Multi-target therapeutic potential of Neem (<i>Azadirachta indica</i>) phytochemicals in Alzheimer's disease: an integrative network pharmacology and molecular dynamics simulation approach.

In silico pharmacology·2025

Same author

Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines.

Molecules (Basel, Switzerland)·2025

Same author

Mitigating Cadmium Toxicity: The Therapeutic Potential of Lactobacillus acidophilus Pro4 in Mice.

Probiotics and antimicrobial proteins·2025

Same author

Design, synthesis, biological evaluation and in silico studies of 2-anilino- 4-(benzimidazol- 1-yl)pyrimidine scaffold as antitumor agents.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2025

Same author

Synthesis, <i>in vitro</i> and <i>in silico</i> studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity <i>via</i> G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II.

Journal of enzyme inhibition and medicinal chemistry·2025

Search research articles

Related Experiment Video

Updated: Jul 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Regorafenib: A comprehensive drug profile.

Ahmed A Abdelgalil¹, Hamad M Alkahtani²

¹Central Laboratory, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology

|February 29, 2024

Summary

This summary is machine-generated.

Regorafenib is an oral tyrosine kinase inhibitor targeting VEGF receptors, approved for metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. This profile details its synthesis, physical and analytical characteristics, and pharmacological profile.

Keywords:

ADME profiles High performance liquid chromatography Methods of chemical synthesis Pharmacological effects Physical profiles Regorafenib Stability

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Experiment Videos

Last Updated: Jul 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Area of Science:

Pharmacology
Medicinal Chemistry
Drug Development

Background:

Regorafenib is an oral small molecule tyrosine kinase inhibitor.
It targets vascular endothelial growth factor (VEGF) receptors.
Approved indications include metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC).

Purpose of the Study:

To provide a comprehensive profile of regorafenib.
To consolidate original and literature data on drug synthesis, physical characteristics, analytical methods, and pharmacology.
To detail the drug's properties and preparation methods.

Main Methods:

Literature review and data compilation.
Analysis of drug synthesis pathways.
Characterization of physical properties (e.g., solubility, stability, thermal analysis, spectroscopy).
Evaluation of analytical techniques (e.g., chromatographic, spectrophotometric, electrochemical).
Assessment of Absorption, Distribution, Metabolism, and Excretion (ADME) profiles.

Main Results:

Detailed description of regorafenib's chemical and physical properties.
Outlined methods and schemes for drug substance preparation.
Comprehensive overview of analytical methodologies for quality control.
Discussion of ADME profiles and pharmacological effects.

Conclusions:

Regorafenib's multifaceted profile is crucial for understanding its therapeutic applications.
This profile serves as a valuable resource for researchers and clinicians.
Further research can build upon the synthesized data for drug optimization and application.